Wall Street equity research analysts tracking Evolus maintain an optimistic 12-month consensus price forecast, with average targets hovering around $14.96 to $15.50 per share. Individual institutional estimates range from a conservative low of roughly $10.10 up to a high of $21.00, driven by projected double-digit revenue growth from its core medical aesthetics portfolio.